ClinicalTrials.gg
RecruitingNCT07848659Updated Sep 30, 2026

Study of Single Doses of HBS-104 in Acutely Sleep-deprived Healthy Participants

A Phase 1 interventional study of HBS-104 and Placebo in Sleep Deprivation, sponsored by Harmony Biosciences Management, Inc.. Recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Harmony Biosciences Management, Inc. (part of Harmony Biosciences Holdings, Inc.) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 146 studies in Sleep Deprivation with a site in United States — 30 open to participants now, 34 under way, none of them phase 3. Sleep Deprivation · United States.

Planned enrollment
112th of 127
12 · median 55
Started
2026
with 7 others
Phase 1
6 of 146
2 open now
Primary completion
2026-10
later than 12 of 33 live
Registered
146th of 146
by date

Among the 146 studies in Sleep Deprivation with a site in United States, this one is the 112th largest by planned enrollment of the 127 interventional ones that give a count, is one of 8 that started in 2026, is one of 6 in phase 1, reaches primary completion later than 12 of the 33 other live ones, and was the 146th registered.

Sleep Deprivation

314 studies on the registry are indexed under Sleep Deprivation; 59 are open to participants now.

Browse Sleep Deprivation studies →

Open to participants now

30 of the 146 studies in Sleep Deprivation with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 Sleep Deprivation studies recruiting now, 11 (26%) set no upper age limit and 28 (65%) stop at 75 or younger; 5 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 146 studies in Sleep Deprivation with a site in United States, or all of them as a file.
02

Study summary

This is a study to evaluate the pharmacodynamic effects, safety, tolerability, and pharmacokinetics of HBS-104 in acutely sleep-deprived healthy adult participants.

Read the detailed description

Single oral doses of HBS-104 (low, medium or high doses) or matching placebo will be administered in 4 double-blind treatment periods in a crossover design. Each treatment period is 4 days in duration (Days -1 to 3) separated by a 7 to 12 day washout interval.

03

Conditions studied

  • Sleep Deprivation

Browse trials for

Keywords

  • Healthy Participants
  • Acute Sleep Deprivation
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide written before any study-related procedures are performed.
  • Be healthy as determined by assessments at the Screening Visit.

Exclusion criteria

Exclusion Criteria:

  • Female with a positive pregnancy test at Screening Visit or upon check-in for Period 1.
  • Is currently breastfeeding or planning to breastfeed over the course of the study. Lactating women must agree not to breastfeed for the duration of the study and for 7 days after their final dose of study drug.

Note: Additional inclusion/exclusion criteria may apply, per protocol

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    Crossover: HBS-104 Low Dose

    Participants will receive a single oral low dose of HBS-104.

    Drug: HBS-104

  • Experimental
    Crossover: HBS-104 Medium Dose

    Participants will receive a single oral medium dose of HBS-104.

    Drug: HBS-104

  • Experimental
    Crossover: HBS-104 High Dose

    Participants will receive a single oral high dose of HBS-104.

    Drug: HBS-104

  • Active comparator
    Crossover: Placebo

    Participants will receive a single oral dose of placebo.

    Drug: Placebo

Interventions

  • DrugHBS-104

    Immediate-release tablets for oral use

  • DrugPlacebo

    Matching placebo tablet

06

What researchers measure

Primary outcomes

  1. Mean Sleep Latency as Assessed by Maintenance of Wakefulness Test (MWT)

    Time frame: Day 2 of each treatment period (each treatment period is 4 days in duration [Days -1 to 3]).

  2. Karolinska Sleepiness Scale (KSS) Score

    Time frame: Days 1 and 2 of each treatment period (each treatment period is 4 days in duration [Days -1 to 3]).

  3. Psychomotor Vigilance Test (PVT) Score

    Time frame: Days 1 and 2 of each treatment period (each treatment period is 4 days in duration [Days -1 to 3]).

Secondary outcomes

  1. Number of Participants with Treatment Emergent Adverse Events

    Time frame: Up to 25 weeks

  2. Serum Concentrations of HBS-104 and Metabolites

    Time frame: Days 1, 2 and 3 of each treatment period (each treatment period is 4 days in duration [Days -1 to 3]).

07

Study locations

1 of 1 sites recruiting
  • Sponsor Clinical Site - New Jersey
    Eatontown, New Jersey 07724, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2026 (actual). Primary completion is estimated for Oct 2026, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2026
First posted
Sep 30, 2026
StartActual
Aug 28, 2026
Primary completionEst.
Oct 30, 2026
CompletionEst.
Feb 18, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07848659
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Aug 28, 2026
Primary completion
Oct 30, 2026 (estimated)
Completion
Feb 18, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Clinical Trials Administrator
Contact
clinicaltrials@harmonybiosciences.com
see email
David Sneiden, MD
study director · Harmony Biosciences Management, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion